1H 2022 Earnings call

August 2022

DISCLAIMER

This presentation (the "Presentation") is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Sofwave Medical Ltd. (the "Company" or "Sofwave") and should not be regarded as a recommendation or an opinion on such matters. The information included in this Presentation is not comprehensive and does not include all the information with respect to the Company and its business required for any decision concerning an investment in the Company's securities. This Presentation includes forecasts, estimates, assessments, expectations and other information, intent or belief pertaining to future events and/or matters, which constitute "forward-looking statements" as defined in the Securities Law 5728-1968, which is based on current expectations, projections and assumptions about future events. Actual results may differ materially due to variety of factors, some of which the Company has no control over and cannot be reasonably foreseen at this date, including, but not limited to: dependency on third parties engaged by or who contracts the Company and its services, change in the overall economy; the duration and severity of the COVID-19 (coronavirus) pandemic and its impact on the Company and on local and global economy and the Company's ability to manage and develop its business. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different to that forecast. Therefore, actual future results, performances or achievements of the Company may differ materially from what is or may be expressed or implied in this Presentation. Certain information and factual statements (including markets or trends) contained herein are based on or derived from publicly available documents or independent third party sources the accuracy of such information and the assumptions on which such information is based have not been independently verified. The past performance information contained herein is not indicative of future results and there can be no assurance that the Company will achieve comparable results or that the Company will be able to implement its investment strategy or achieve any investment objective.

| 2

1H 2022 Earning Call

Presenters:

  • Shimon Eckhouse, Co-Founder and Chairman
  • Lou Scafuri, CEO
  • Assaf Korner, CFO

| 3

1H 2022 in Numbers

$13.7M

Revenues H1/22

+34% YoY Growth

74.7% GM

1H 2022

$2.9M Recurring

Revenue

+202% YoY Growth

$36M Cash

As of June 30, 2022

$8.1M Revenues

Q2/22

+31% YoY Growth

4 Major Beauty

Awards

| 4

First Half 2022 Highlights

  • Achieved 34.4% revenue growth despite global pandemic and major supply chain challenges
  • Recurring revenue continues to grow substantially: over 20% of total revenue; over 25,000 treatments in 6 months vs. ~25,000 for the entire 2021
  • Key Collaboration and Distribution agreement with a major partner for the Chinese market
  • Significant brand awareness - over 350,000 followers on social media
  • Expanded widespread acceptance by global KOLs: 8 of 15 top Cosmetics Dermatologists in the US are Sofwave users (Newsweek ranking June 2022)
  • Continue to expand US sales team to 30
  • International leadership team strengthened with the addition of two highly experienced regional managers
  • Completed patient enrollment in cellulite clinical trial

| 5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sofwave Medical Ltd. published this content on 16 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 August 2022 06:01:08 UTC.